Abstract #1003943: Dapagliflozin is Superior to Metformin as Monotherapy in Improving HbA1c and BMI in Drug Naive Type 2 Diabetic Adults

Type 2 diabetes is a myocardial equivalent and cardiovascular disease is the major cause of mortality among people with diabetes. Drugs that are capable of reducing the adverse cardiac events in addition to improving glycemia can lower morbidity and mortality in diabetes. Metformin and SGLT2 inhibitors are two diabetic medicines with proven cardic benefits. We studied the glucose lowering potential of dapagliflozin and compared that with metformin in subjects who never received an antidiabetic medication. We also looked into the adverse reactions of the individual agents.